Literature DB >> 1822343

Dystrophin abnormalities in polymyositis and dermatomyositis.

C A Sewry1, A Clerk, J Z Heckmatt, T Vyse, V Dubowitz, P N Strong.   

Abstract

The expression of dystrophin in muscle biopsies from nine cases of polymyositis, ten cases of juvenile dermatomyositis and three adults with dermatomyositis was studied by Western blot analysis and immunocytochemistry. Five antibodies corresponding to different N- and C-terminal regions of the dystrophin gene were used. Sixteen of the 22 cases (73%) showed an abnormality in the expression of dystrophin on Western blot analysis, either with a reduced molecular weight protein or a reduced amount. Immunostaining was abnormal in 11 out of 19 cases (58%) and showed varying degrees of discontinuity or loss of sarcolemmal staining. Immunolabelling of these areas with antibodies to beta-spectrin was normal implying that the changes were not caused by a loss of the sarcolemma. These results show that secondary changes in the expression of dystrophin can occur in the absence of an abnormality in the corresponding gene and that dystrophin cannot be used in isolation as a diagnostic marker for muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822343     DOI: 10.1016/0960-8966(91)90119-d

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Improved skeletal muscle fatigue resistance in experimental autoimmune myositis mice following high-intensity interval training.

Authors:  Takashi Yamada; Yuki Ashida; Katsuyuki Tamai; Iori Kimura; Nao Yamauchi; Azuma Naito; Nao Tokuda; Håkan Westerblad; Daniel C Andersson; Koichi Himori
Journal:  Arthritis Res Ther       Date:  2022-06-27       Impact factor: 5.606

2.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

3.  Muscle Weakness in Myositis: MicroRNA-Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies.

Authors:  Travis B Kinder; Christopher R Heier; Christopher B Tully; Jack H Van der Muelen; Eric P Hoffman; Kanneboyina Nagaraju; Alyson A Fiorillo
Journal:  Arthritis Rheumatol       Date:  2020-05-31       Impact factor: 10.995

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.